Article
Pediatrics
Elisabetta Schiavello, Filippo Spreafico, Francesco Barretta, Giulia Meraviglia, Veronica Biassoni, Monica Terenziani, Luna Boschetti, Giovanna Gattuso, Stefano Chiaravalli, Luca Bergamaschi, Nadia Puma, Giovanna Sironi, Olga Nigro, Marta Podda, Cristina Meazza, Michela Casanova, Andrea Ferrari, Roberto Luksch, Maura Massimino
Summary: Low-intensity chemotherapy for 9 weeks without intrathecal prophylaxis is sufficient for curing children with early-stage non-Hodgkin's lymphomas (ES-NHL), without jeopardizing the excellent survival rate of this disease.
Article
Medicine, General & Internal
Stephen M. Ansell, John Radford, Joseph M. Connors, Monika Dlugosz-Danecka, Won-Seog Kim, Andrea Gallamini, Radhakrishnan Ramchandren, Jonathan W. Friedberg, Ranjana Advani, Martin Hutchings, Andrew M. Evens, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Hyeon-Seok Eom, Jeremy S. Abramson, Cassie Dong, Frank Campana, Keenan Fenton, Markus Puhlmann, David J. Straus
Summary: The study found that using A+AVD for the treatment of stage III or IV Hodgkin's lymphoma provides a survival advantage over ABVD.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Editorial Material
Medicine, General & Internal
Dan L. Longo, James O. Armitage
Summary: Treatment for Hodgkin's lymphoma has been a success in modern medicine. The once fatal disorder is now curable in the majority of patients, even in advanced stages. The focus of treatment is on maintaining high cure rates while reducing toxic effects. The best approach for advanced-stage, high-risk patients is currently debated.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Thomas M. Habermann
Summary: Several important updates have emerged in the management of early-stage diffuse large B-cell lymphoma, including the approval of the R-CHOP regimen for international use and studies on the optimal number of treatment cycles without radiation therapy. Tailored treatment strategies are recommended for patients with extranodal diseases, with molecular subtype evaluations potentially changing treatment approaches.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Hematology
Akash Parekh, Frank G. Keller, Kathleen M. McCarten, Sandy Kessel, Steve Cho, Qinglin Pei, Yue Wu, Sharon M. Castellino, Louis S. Constine, Cindy L. Schwartz, David Hodgson, Kara M. Kelly, Bradford S. Hoppe
Summary: The COG trial AHOD0431 aimed to improve the outcome of pediatric classic Hodgkin lymphoma by reducing systemic therapy and utilizing response-adapted involved-field radiotherapy (IFRT). The study found that the PET1 response after 1 cycle of chemotherapy had a significant impact on the efficacy of IFRT and the pattern of relapse.
Article
Oncology
Susan Luong, Claire Mockler, Jessica Pudwell, Wenbin Li, Jill Dudebout, Maria P. Velez
Summary: This study examined the effects of Hodgkin's lymphoma and its treatment on reproductive health in adolescent and young adult females. The risk of infertility and premature ovarian insufficiency was higher in Hodgkin's lymphoma patients, particularly those who received combined chemotherapy and radiotherapy. These findings highlight the importance of pre-treatment fertility counseling and reproductive health surveillance for AYAs diagnosed with Hodgkin's lymphoma.
JOURNAL OF CANCER SURVIVORSHIP
(2023)
Article
Neurosciences
Dan Fayette, Veronika Jurickova, Tomas Kozak, Heidi Mocikova, Lubica Gaherova, Iveta Fajnerova, Jiri Horacek
Summary: Chemotherapy-related cognitive impairment (CRCI) is common in Hodgkin's lymphoma (HL) patients. This study found that HL patients had impaired cognitive performance compared to healthy controls, and these impairments persisted even 6 months after chemotherapy. The study suggests that cognitive impairment may exist in HL patients prior to treatment and is exacerbated by chemotherapy.
NEUROSCIENCE LETTERS
(2023)
Article
Oncology
Miki Hoshi, Nobuaki Kobayashi, Katsushi Tanaka, Kohei Somekawa, Ayami Kaneko, Ami Izawa, Kenichi Seki, Yoichi Tagami, Ayako Aoki, Hiroaki Fujii, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Mai Matsumura, Makiko Enaka, Maki Hagihara, Takeshi Kaneko
Summary: Lung lesions of Hodgkin's lymphoma are rare and difficult to diagnose by nonsurgical biopsy, with a low diagnostic success rate of TBB. Surgical biopsy is essential for improving diagnostic accuracy in such cases.
Article
Hematology
Karan L. Chohan, Jason R. Young, Scott Lester, Muhamad Alhaj Moustafa, Allison Rosenthal, Han W. Tun, Bradford S. Hoppe, Patrick B. Johnston, Ivana N. MicaIlef, Thomas M. Habermann, Stephen M. Anse
Summary: This study compared the efficacy of combined modality therapy and chemotherapy-alone in early-stage classical Hodgkin lymphoma (cHL) patients. The results showed that combined modality therapy was beneficial for patients with PET2-positive and unfavorable disease, while chemotherapy-alone achieved comparable outcomes in PET2-negative, favorable, and non-bulky disease patients.
Article
Multidisciplinary Sciences
Akram Al-Ibraheem, Farah Anwer, Malik E. Juweid, Qaid Ahmed Shagera, Aysar N. Khalaf, Shahed Obeidat, Areen Mansour, Mohammad Ma'koseh, Khalid Halahleh, Imad Jaradat, Nidal Almasri, Asem Mansour
Summary: The study assessed the predictive value of interim FDG-PET/CT in HL patients treated with ABVD chemotherapy. The results showed that iPET was strongly associated with treatment response and prognosis, and could help tailor therapy to individual patients.
SCIENTIFIC REPORTS
(2022)
Article
Multidisciplinary Sciences
Pierre Pinochet, Edgar Texte, Aspasia Stamatoullas-Bastard, Pierre Vera, Sorina-Dana Mihailescu, Stephanie Becker
Summary: The study demonstrates the prognostic value of initial total metabolic tumor volume (TMTV) in predicting outcomes for patients with advanced-stage Hodgkin's lymphoma (HL). TMTV is useful for predicting 5-year progression-free survival and PET response after chemotherapy, and remains a baseline prognostic factor even when considering other treatment variables.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Yufan Tang, Ting Yan, Wangwang Qiu, Zheng Ding, Youben Fan, Qiong Jiao, Zhili Yang
Summary: The study aims to explore the optimal treatment for stage IE primary thyroid lymphoma (PTL). By comparing the survival outcomes and treatment modalities, the study found that surgery is a viable treatment option.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Ranjana H. Advani
Summary: The goal of first-line therapy in classic Hodgkin lymphoma is to balance risk versus benefit to the individual while increasing efficacy and reducing toxicity. The ABVD regimen is well tolerated but slightly less effective, while BV-AVD falls between ABVD and escalated BEACOPP on the cure/morbidity scale. In patients with interim PET-negative cHL, de-escalating therapy does not impact overall survival.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Multidisciplinary Sciences
Debra Van Egeren, Khushi Kohli, Jeremy L. Warner, Philippe L. Bedard, Gregory Riely, Eva Lepisto, Deborah Schrag, Michele LeNoue-Newton, Paul Catalano, Kenneth L. Kehl, Franziska Michor
Summary: The study found a significant association between TP53 mutations and distant metastasis in non-small cell lung cancer (NSCLC) patients, and TP53 mutations were more prevalent in patients with a history of smoking, suggesting a higher risk of distant metastasis in these patients.
SCIENTIFIC REPORTS
(2022)